JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins... Show more
The Moving Average Convergence Divergence (MACD) for JCRRF turned positive on July 09, 2025. Looking at past instances where JCRRF's MACD turned positive, the stock continued to rise in of 10 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 03, 2025. You may want to consider a long position or call options on JCRRF as a result. In of 11 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.189) is normal, around the industry mean (5.632). P/E Ratio (44.053) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.015) settles around the average of (0.161) among similar stocks. P/S Ratio (4.845) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JCRRF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JCRRF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
Industry PharmaceuticalsMajor
A.I.dvisor tells us that JCRRF and SNYNF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JCRRF and SNYNF's prices will move in lockstep.
Ticker / NAME | Correlation To JCRRF | 1D Price Change % | ||
---|---|---|---|---|
JCRRF | 100% | N/A | ||
SNYNF - JCRRF | 8% Poorly correlated | +2.28% | ||
SCLX - JCRRF | 4% Poorly correlated | +32.14% | ||
MIRA - JCRRF | 2% Poorly correlated | +8.02% | ||
CSWYF - JCRRF | 0% Poorly correlated | N/A | ||
VRBCF - JCRRF | -0% Poorly correlated | N/A | ||
More |